Men have higher concentrations of ACE2 in their blood.
The FDA recently approved AstraZeneca’s Farxiga (dapagliflozin) for the treatment of heart failure with reduced ejection fraction (HFrEF) in adults with and without type 2 diabetes, marking the first time a drug in a class developed for diabetes was approved for heart failure even if diabetes is not present.
Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.
The first FDA-approved product for NASH on the horizon.
A new class of drugs for high cholesterol and a novel peanut allergy treatment lead expected approvals.
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.
In the past week, the migraine prevention drug market has suddenly heated up, with 2 new approvals by FDA.
Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
Albert A. Rizzo, MD, senior medical advisor for the American Lung Association, says the increasing number of drugs in the pipeline could improve airflow and address the underlying disease process.